Stromal interaction essential for vascular endothelial growth factor A-induced tumour growth via transforming growth factor-Β signalling

British Journal of Cancer

Volumn 105, Issue 12, 2011, Pages 1856-1863

  Weidenaar, A C ^a   Ter Elst, A ^a   Kampen, K R ^a   Meeuwsen De Boer, T G J ^a   De Jonge, H J M ^a   Scherpen, F J G ^a   Den Dunnen, W F A ^b   Kamps, W A ^a   De Bont, E S J M ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Angiogenesis; Stroma; TGF ; Tumourigenesis; VEGFA

Indexed keywords

COLONY STIMULATING FACTOR 1; CXCL9 CHEMOKINE; GAMMA INTERFERON; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 7; SMAD5 PROTEIN; SMAD7 PROTEIN; SOS PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME; UPREGULATION; ANIMAL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL NEOPLASM; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; IMMUNOHISTOCHEMISTRY; METABOLISM; MOUSE MUTANT; NONOBESE DIABETIC MOUSE; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; STROMA CELL; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASMS, EXPERIMENTAL; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STROMAL CELLS; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84856001094     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.460     Document Type: Article

References (25)

1. Aguayo A, Estey E, Kantarjian H, Mansouri T, Gidel C, Keating M, Giles F, Estrov Z, Barlogie B, Albitar M (1999) Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 94: 3717-3721
2. Ayala F, Dewar R, Kieran M, Kalluri R (2009) Contribution of bone microenvironment to leukemogenesis and leukemia progression. Leukemia 23: 2233-2241
3. Bellamy WT, Richter L, Frutiger Y, Grogan TM (1999) Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 59: 728-733 (Pubitemid 29076074)
4. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407: 249-257
5. Dankbar B, Padro T, Leo R, Feldmann B, Kropff M, Mesters RM, Serve H, Berdel WE, Kienast J (2000) Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 95: 2630-2636 (Pubitemid 30210543)
6. de Bont ES, Fidler V, Meeuwsen T, Scherpen F, Hahlen K, Kamps WA (2002) Vascular endothelial growth factor secretion is an independent prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients. Clin Cancer Res 8: 2856-2861 (Pubitemid 35025730)
7. de Bont ES, Rosati S, Jacobs S, Kamps WA, Vellenga E (2001) Increased bone marrow vascularization in patients with acute myeloid leukaemia: a possible role for vascular endothelial growth factor. Br J Haematol 113: 296-304 (Pubitemid 32523131)
8. Dong M, Blobe GC (2006) Role of transforming growth factor-beta in hematologic malignancies. Blood 107: 4589-4596 (Pubitemid 43882602)
9. Elliott RL, Blobe GC (2005) Role of transforming growth factor Beta in human cancer. J Clin Oncol 23: 2078-2093 (Pubitemid 46211385)
10. Fiedler W, Graeven U, Ergun S, Verago S, Kilic N, Stockschlader M, Hossfeld DK (1997) Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 89: 1870-1875 (Pubitemid 27132100)
11. Grandage VL, Gale RE, Linch DC, Khwaja A (2005) PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia 19: 586-594 (Pubitemid 40521164)
12. Hermani A, De Servi B, Medunjanin S, Tessier PA, Mayer D (2006) S100A8 and S100A9, activate MAP kinase and NF-kappaB signaling pathways and trigger translocation of RAGE in human prostate cancer cells. Exp Cell Res 312: 184-197 (Pubitemid 41721180)
13. Huang M, Sharma S, Zhu LX, Keane MP, Luo J, Zhang L, Burdick MD, Lin YQ, Dohadwala M, Gardner B, Batra RK, Strieter RM, Dubinett SM (2002) IL-7 inhibits fibroblast TGF-beta production and signaling in pulmonary fibrosis. J Clin Invest 109: 931-937
14. Kim WS, Park C, Jung YS, Kim HS, Han J, Park CH, Kim K, Kim J, Shim YM, Park K (1999) Reduced transforming growth factor-beta type II receptor (TGF-beta RII) expression in adenocarcinoma of the lung. Anticancer Res 19: 301-306 (Pubitemid 29168253)
15. Kleeff J, Ishiwata T, Maruyama H, Friess H, Truong P, Buchler MW, Falb D, Korc M (1999) The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene 18: 5363-5372 (Pubitemid 29469224)
16. Lee CY, Tien HF, Hu CY, Chou WC, Lin LI (2007) Marrow angiogenesisassociated factors as prognostic biomarkers in patients with acute myelogenous leukaemia. Br J Cancer 97: 877-882
17. Lewis TS, Shapiro PS, Ahn NG (1998) Signal transduction through MAP kinase cascades. Adv Cancer Res 74: 49-139 (Pubitemid 28193546)
18. Liu D, Jia H, Holmes DI, Stannard A, Zachary I (2003) Vascular endothelial growth factor-regulated gene expression in endothelial cells: KDRmediated induction of Egr3 and the related nuclear receptors Nur77, Nurr1, and Nor1. Arterioscler Thromb Vasc Biol 23: 2002-2007 (Pubitemid 37433192)
19. Mani M, Carrasco DE, Zhang Y, Takada K, Gatt ME, Dutta-Simmons J, Ikeda H, Diaz-Griffero F, Pena-Cruz V, Bertagnolli M, Myeroff LL, Markowitz SD, Anderson KC, Carrasco DR (2009) BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells. Cancer Res 69: 7577-7586
20. Nicolas E, Ramus C, Berthier S, Arlotto M, Bouamrani A, Lefebvre C, Morel F, Garin J, Ifrah N, Berger F, Cahn JY, Mossuz P (2011) Expression of S100A8 in leukemic cells predicts poor survival in de novo AML patients. Leukemia 25: 57-65
21. Padro T, Ruiz S, Bieker R, Burger H, Steins M, Kienast J, Buchner T, Berdel WE, Mesters RM (2000) Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 95: 2637-2644 (Pubitemid 30210544)
22. Siapati EK, Papadaki M, Kozaou Z, Rouka E, Michali E, Savvidou I, Gogos D, Kyriakou D, Anagnostopoulos NI, Vassilopoulos G (2011) Proliferation and bone marrow engraftment of AML blasts is dependent on beta-catenin signalling. Br J Haematol 152: 164-174
23. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, Dubois RN (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93: 705-716 (Pubitemid 28257578)
24. Ulloa L, Doody J, Massague J (1999) Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature 397: 710-713
25. Weidenaar AC, de Jonge HJ, Fidler V, Ter Elst A, Meeuwsen-de Boer T, Douwes J, Bouma-Ter Steege JC, Hahlen K, Kamps WA, de Bont ES (2008) Addition of PTK787/ZK 222584 can lower the dosage of amsacrine to achieve equal amounts of acute myeloid leukemia cell death. Anticancer Drugs 19: 45-54 (Pubitemid 350190967)